

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q92967

Noboru YAMAZAKI, et al.

Appln. No.: 10/566,566

Group Art Unit: Not Yet Assigned

Confirmation No.: 6156

Examiner: Not Yet Assigned

Filed: February 1, 2006

For: TARGET-DIRECTED AND ENTERIC ABSORPTION-CONTROLLLED
LIPOSOME HAVING SUGAR CHAIN AND CANCER REMEDY AND
DIAGNOSTIC CONTAINING THE SAME

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy an International Search Report in a counterpart application citing such documents.

INFORMATION DISCLOSURE STATEMENT
U.S. Application No.: 10/566,566

Attorney Docket Q92967

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Rehita S. Rathinam
Registration No. 53,502

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: August 21, 2006

Substitute for Form 1449 A & B/PTO				Complete if Known	
<u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u>				Application Number	10/566,566
				Confirmation Number	6156
				Filing Date	February 1, 2006
				First Named Inventor	Noboru YAMAZAKI
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

NON PATENT LITERATURE DOCUMENTS

NONPATENT EXTRASPECIFIC DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		International Search Report dated November 9, 2004.	
		HONG, Ruey-Long et al., "Direct Comparison of Liposomal Doxorubicin With or Without Polyethylene Glycol Coating in C-26 Tumor-bearing Mice: Is Surface Coating With Polyethylene Glycol Beneficial?" Clinical Cancer Research, 1999, pages 3645 to 3652, Vol. 5.	
		KAMPS, Jan A.A.M. et al., "Massive Targeting of Liposomes, Surfase-Modified With Anionized Albumins, to Hepatic Endothelial Cells", Proc. Natl. Acad. Sci. 1997, pages 11681 to 11685, Vol. 94, USA.	
		KOLE, Labanyamoy et al., "Synergistic Effect of Interferon- γ and Mannosylated Loposome-incorporated Doxorubisin in the Therapy of Experimental Visceral Leishmaniasis", 1999, pages 811 to 820, Vol. 180.	
		TAKEUCHI, Hirofumi et al., "Passive Targeting of Doxorubicine with Polymer Coated Liposomes in Tumor Bearing Rat", Biol. Pharm. Bull., 2001, pages 795 to 799, Vol. 24.	
		YAMAZAKI, Noboru et al., "Preparation and Characterization of Neoglycoprotein-liposome Conjugates: A Promising Approach to Developing Drug Delivery Materials Applying Sugar Chain Ligands", Trends in Glycoscience and Glycotechnology, 2001, pages 319 to 329, Vol. 13, No. .	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.